Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2013

View Archived Issues

Biomarker analysis and mental fitness testing for driving aptitude in patients with cirrhosis

Gilead Sciences reviews events of second quarter 2013

Targeting Abeta oligomers for the treatment of Alzheimer's disease

Bayer discloses novel sGC activators for cardiovascular disorders

Baltic Bio synthesizes new AMPK activators for diabetes

Cellmid collaborates on marker for colorectal cancer diagnosis

Preclinical and clinical evaluation of a snake venom polypeptide as an antithrombotic

Ex vivo evaluation of a bispecific antibody for the treatment of patients with hemophilia A

Phase II study of SHACT meets efficacy and safety endpoints

Signature Therapeutics receives award to advance abuse-deterrent oxycodone

Nektar Therapeutics completes enrollment in phase III BEACON study

ReGenX Biosciences and Audentes Therapeutics to develop NAV vector treatments

Summit awarded grant to develop DMD therapy

Spanish researchers discover biomarker for Lewy body dementia diagnosis

Omeros submits NDA to the FDA for OMS-302

IntelligentMDx receives FDA clearance for vancomycin-resistant enterococci assay

BioDelivery Sciences submits NDA to FDA for Bunavail

PrEP trial to evaluate prevention using antiretroviral drugs in HIV-negative individuals

S1 Biopharma initiates phase IIa trial of Lorexys in premenopausal women with HSDD

New company AveXis to focus on new technology for disease treatment

OncoTherapy Science identifies potent drug candidates for a novel kinase target

Cubist Pharmaceuticals signs agreements to acquire two companies

OncoTherapy's phase III trial of peptide cocktail vaccine for pancreatic cancer remains on schedule

MolecularMD obtains license for cancer diagnosis technology

Takeda receives marketing authorization in China for Nesina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.